Plant ID: NPO15095
Plant Latin Name: Hippophae rhamnoides
Taxonomy Genus: Hippophae
Taxonomy Family: Elaeagnaceae
NCBI TaxonomyDB:
193516
Plant-of-the-World-Online:
n.a.
Astringent; Cancer; Cardiac; Poultice; Tonic; Vermifuge
India; Finland; China; Russia
TSHR; NPSR1; | |
FFAR1; FFAR4; ADRA2B; GPR35; | |
TDP1; RECQL; ALPL; PIK3CA; PIK3CB; GLO1; ALOX12; AKR1B1; HSD17B2; HSD17B10; HPGD; NOX4; ALOX15; NQO2; APEX1; POLB; | |
ACHE; | |
TOP2A; | |
FLT3; TEK; KDR; INSR; AXL; CDK1; EGFR; PIM1; MET; SRC; IGF1R; AURKB; NUAK1; HASPIN; CSNK2A1; | |
CA2; CA12; CA9; CA14; CA7; CA4; | |
PPARA; | |
ESR1; | |
TYR; PTGS2; | |
KDM4E; | |
MMP1; MMP9; MMP2; | |
AHR; NFKB1; | |
FUT7; | |
SLC22A6; SLCO1B1; | |
LMNA; FABP3; FABP5; SMAD3; FABP4; MAPT; HSPA1A; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | HASPIN | Serine/threonine-protein kinase haspin | Q8TF76 | CHEMBL1075163 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.874E-12 | 8.051E-09 | CA12, CA14, CA2, CA4, CA7, CA9 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 3.939E-09 | 1.505E-06 | AXL, EGFR, INSR, MET, NOX4, PIK3CA, PIK3CB, SRC, TEK |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.152E-08 | 3.585E-06 | CA12, CA14, CA2, CA4, CA7, CA9 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.300E-08 | 5.962E-06 | CA2, CA4, CA9, EGFR, HPGD, SLC22A6, SLCO1B1, TEK, TSHR |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 5.068E-08 | 1.173E-05 | ALPL, APEX1, CYP1A1, CYP1B1, EGFR, ESR1, FLT3, NFKB1, NOX4, PTGS2, SRC |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 5.119E-08 | 1.173E-05 | IGF1R, INSR, PIK3CA, PIK3CB |
MF | GO:0005488; binding | GO:0005524; ATP binding | 1.630E-07 | 3.197E-05 | AURKB, AXL, CDK1, CSNK2A1, EGFR, FLT3, HASPIN, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIK3CA, PIK3CB, PIM1, RECQL, SRC, TEK, TOP2A |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.867E-07 | 3.567E-05 | CA12, CA2, CA4, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.785E-07 | 4.930E-05 | ALOX12, ALOX15, HPGD, PTGS2 |
MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 3.655E-07 | 6.367E-05 | ACHE, APEX1, CSNK2A1, EGFR, FLT3, IGF1R, INSR, KDR, L3MBTL1, MAPT, MMP9, PIM1, PPARA, SMAD3, SRC, TSHR |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 3.886E-07 | 6.611E-05 | CYP1A1, LMNA, MMP2, NOX4, PPARA, PTGS2, SMAD3, SRC, TEK |
MF | GO:0005488; binding | GO:0020037; heme binding | 4.032E-07 | 6.806E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS2, SRC |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.901E-07 | 9.518E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 7.368E-07 | 1.133E-04 | EGFR, IGF1R, INSR, KDR, SRC |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.055E-06 | 1.563E-04 | CA12, CA2, CA4, CA7, CA9, ESR1, GLO1, L3MBTL1, MMP1, MMP2, MMP9, NQO2, PPARA, SMAD3 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.329E-06 | 1.844E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0005488; binding | GO:0005504; fatty acid binding | 2.606E-06 | 3.127E-04 | FABP3, FABP4, FABP5, FFAR4 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 2.747E-06 | 3.242E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 3.569E-06 | 4.006E-04 | ALOX15, ALPL, EGFR, MMP2, MMP9, TEK |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 3.769E-06 | 4.166E-04 | EGFR, INSR, KDR |
BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 4.495E-06 | 4.822E-04 | ACHE, AKR1B1, ALOX12, ALOX15, CSNK2A1, CYP1A1, CYP3A4, HSD17B2, PIK3CA, PIK3CB, PTGS2 |
BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 4.971E-06 | 5.280E-04 | ADRA2B, CDK1, EGFR, FLT3, INSR, NOX4, PIK3CB, SRC |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 5.267E-06 | 5.540E-04 | AHR, CSNK2A1, KDR, MAPT |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.371E-06 | 5.623E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 6.265E-06 | 6.405E-04 | AXL, KDR, PIK3CA, PIK3CB, SRC |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 7.071E-06 | 6.967E-04 | ALPL, AXL, CYP1A1, CYP1A2, HPGD, NFKB1, PTGS2, SRC |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 7.184E-06 | 7.046E-04 | ALOX15, EGFR, FFAR4, KDR, NOX4, SRC, TEK |
MF | Unclassified; | GO:0004872; receptor activity | 7.392E-06 | 7.186E-04 | ADRA2B, AHR, AXL, EGFR, ESR1, FFAR1, FFAR4, FLT3, GPR35, HPGD, IGF1R, INSR, KDR, MET, NPSR1, PPARA, TEK, TSHR |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 8.181E-06 | 7.813E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 8.484E-06 | 8.032E-04 | AHR, AXL, CSNK2A1, EGFR, ESR1, PPARA, SRC, TOP2A |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.295E-05 | 1.137E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.295E-05 | 1.137E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.295E-05 | 1.137E-03 | ALOX12, ALOX15 |
MF | GO:0005488; binding | GO:0042562; hormone binding | 1.416E-05 | 1.230E-03 | ACHE, EGFR, IGF1R, INSR, NQO2 |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 1.447E-05 | 1.246E-03 | EGFR, INSR, PTGS2, SMAD3 |
BP | GO:0032502; developmental process | GO:0007568; aging | 2.019E-05 | 1.697E-03 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB, PTGS2 |
BP | GO:0009987; cellular process | GO:0007346; regulation of mitotic cell cycle | 2.358E-05 | 1.930E-03 | APEX1, AURKB, CDK1, CYP1A1, EGFR, HSPA1A, INSR, L3MBTL1, PIM1, SMAD3, TOP2A |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.489E-05 | 2.007E-03 | ALOX12, ALOX15, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
MF | Unclassified; | GO:0032403; protein complex binding | 2.571E-05 | 2.058E-03 | ACHE, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, MMP9, PPARA, SMAD3, SRC, TSHR |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 2.989E-05 | 2.358E-03 | AURKB, CDK1, HASPIN |
BP | GO:0040007; growth | GO:0045927; positive regulation of growth | 3.799E-05 | 2.865E-03 | ALOX12, CDK1, CSNK2A1, EGFR, INSR, MAPT, PIM1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.875E-05 | 2.865E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 3.875E-05 | 2.865E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.875E-05 | 2.865E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 3.875E-05 | 2.865E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 3.875E-05 | 2.865E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 4.691E-05 | 3.383E-03 | CDK1, EGFR, IGF1R, INSR |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 4.928E-05 | 3.524E-03 | ADRA2B, AXL, PIK3CA, PIK3CB, SRC |
MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 4.971E-05 | 3.538E-03 | AHR, ESR1, PPARA |
BP | GO:0009987; cellular process | GO:0030154; cell differentiation | 5.657E-05 | 3.948E-03 | ALPL, AXL, CDK1, CYP1A1, ESR1, FABP4, FFAR4, FLT3, FUT7, GLO1, KDR, MAPT, MMP2, MMP9, NOX4, PTGS2, SMAD3, TOP2A |
CC | GO:0044464; cell part | GO:0005737; cytoplasm | 5.716E-05 | 3.964E-03 | AHR, AKR1B1, ALOX12, APEX1, CA2, CYP3A4, EGFR, ESR1, FABP3, FABP4, FABP5, GLO1, HASPIN, HSD17B10, HSPA1A, MAPT, NFKB1, NPSR1, NUAK1, PIK3CA, PIK3CB, PIM1, POLB, PTGS2, RECQL, SMAD3, SRC, TDP1, TEK, TYR |
BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 5.785E-05 | 3.986E-03 | CA2, PTGS2, SRC |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.785E-05 | 3.986E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 6.093E-05 | 4.133E-03 | FFAR4, NFKB1, PPARA, SMAD3, TEK |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 6.420E-05 | 4.289E-03 | CYP1B1, HPGD, MAPT, MMP9, NOX4, PIK3CB, PTGS2, SMAD3, SRC, TOP2A |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 6.681E-05 | 4.435E-03 | HPGD, MMP2, MMP9 |
BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 7.171E-05 | 4.718E-03 | CA2, CA9, EGFR, ESR1, MET, SMAD3, SRC |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 7.663E-05 | 4.981E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 7.731E-05 | 4.981E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.731E-05 | 4.981E-03 | CYP1A2, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 8.717E-05 | 5.513E-03 | CYP1A2, EGFR, ESR1, HPGD, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 9.621E-05 | 5.935E-03 | EGFR, MET, PIK3CA, PIK3CB |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 9.900E-05 | 6.073E-03 | FABP3, FABP4, FABP5 |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.090E-04 | 6.537E-03 | EGFR, IGF1R, INSR, KDR, TEK |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 1.260E-04 | 7.356E-03 | ACHE, FLT3, HPGD, MAPT, NFKB1, NQO2, PTGS2, SLC22A6, SMAD3, TOP2A, TYR |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.286E-04 | 7.366E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.286E-04 | 7.366E-03 | CYP1A1, CYP3A4 |
CC | GO:0016020; membrane | GO:0005901; caveola | 1.279E-04 | 7.366E-03 | INSR, PTGS2, SLC22A6, SRC |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.293E-04 | 7.387E-03 | ADRA2B, AXL, FFAR1, FFAR4, FLT3, GPR35, IGF1R, INSR, KDR, MET, NPSR1, SLC22A6, SLCO1B1, TEK, TSHR |
BP | GO:0008152; metabolic process | GO:0016572; histone phosphorylation | 1.399E-04 | 7.896E-03 | AURKB, CDK1, HASPIN |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.557E-04 | 8.581E-03 | AXL, IGF1R, INSR |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 1.725E-04 | 9.328E-03 | FLT3, SRC, TEK |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.753E-04 | 9.449E-03 | ALOX15, EGFR, PPARA, SMAD3 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.172E-09 | 1.187E-07 | PIK3CA, SRC, MMP2, KDR, PIK3CB, ESR1, MMP9, MET, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.983E-09 | 1.187E-07 | PIK3CA, SRC, MMP2, PIK3CB, ESR1, MMP9, EGFR, HSPA1A |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.773E-11 | 2.907E-09 | CA12, CA2, CA4, CA7, CA9, CA14 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.195E-08 | 3.921E-07 | SMAD3, PIK3CA, FLT3, MMP1, MMP2, PIK3CB, PTGS2, MET, MMP9, EGFR, NFKB1, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 7.067E-09 | 2.898E-07 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.079E-08 | 5.682E-07 | INSR, HSD17B2, CYP1A1, CYP1B1, PTGS2, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 5.087E-08 | 1.043E-06 | PIK3CA, SRC, INSR, KDR, TEK, PIK3CB, MET, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 4.178E-08 | 9.788E-07 | FABP4, PIK3CA, INSR, PIK3CB, PTGS2, TSHR |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 9.513E-08 | 1.560E-06 | PIK3CA, INSR, KDR, TEK, PIK3CB, MET, EGFR, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 7.182E-08 | 1.309E-06 | PIK3CA, INSR, TEK, PIK3CB, EGFR, NFKB1, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.441E-06 | 1.970E-05 | SMAD3, PIK3CA, MMP2, PIM1, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 2.855E-06 | 2.847E-05 | PIK3CA, INSR, KDR, TEK, PIK3CB, MET, EGFR, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 3.087E-07 | 4.602E-06 | MMP1, SRC, MMP2, MMP9, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.651E-06 | 2.083E-05 | PIK3CA, FLT3, PIM1, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 2.321E-06 | 2.538E-05 | PIK3CA, SRC, KDR, PIK3CB, PTGS2 |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 2.951E-06 | 2.847E-05 | PIK3CA, INSR, PIK3CB, HSPA1A, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 3.440E-06 | 3.134E-05 | SMAD3, PIK3CA, PIK3CB, EGFR, NFKB1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.802E-06 | 2.111E-05 | CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 6.761E-06 | 4.821E-05 | PIK3CA, SRC, KDR, PIK3CB, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.707E-06 | 3.200E-05 | PIK3CA, FLT3, PIK3CB, MET, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 4.944E-06 | 3.861E-05 | PIK3CA, PIK3CB, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 9.146E-06 | 6.000E-05 | PIK3CA, PIM1, CYP1B1, PTGS2, MMP9, MET, EGFR, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 5.299E-06 | 3.950E-05 | PIK3CA, SRC, PIK3CB, ESR1, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 7.142E-06 | 4.881E-05 | SMAD3, PIK3CA, INSR, PIK3CB, EGFR, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.219E-05 | 7.402E-05 | SMAD3, PIK3CA, SRC, PIK3CB, MMP9, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 4.291E-06 | 3.518E-05 | FABP3, FABP4, FABP5, MMP1, PPARA |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.501E-05 | 8.793E-05 | PIK3CA, PIK3CB, EGFR, NFKB1, IGF1R |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 3.369E-05 | 1.842E-04 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 1.959E-05 | 1.108E-04 | PIK3CA, INSR, PIK3CB, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.006E-05 | 6.344E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, PTGS2 |
09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 7.549E-05 | 3.641E-04 | CSNK2A1, PIK3CA, CDK1, PIK3CB, NFKB1, HSPA1A |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 4.182E-05 | 2.079E-04 | PIK3CA, PIK3CB, PTGS2, MMP9, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 3.977E-05 | 2.052E-04 | HPGD, FLT3, MMP9, MET, NFKB1, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 4.003E-05 | 2.052E-04 | PIK3CA, INSR, PIK3CB, PPARA, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 8.188E-05 | 3.730E-04 | POLB, PIK3CA, SRC, CDK1, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 1.147E-04 | 4.822E-04 | PIK3CA, CSNK2A1, PIK3CB, NFKB1, HSPA1A |
09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.032E-04 | 4.455E-04 | PIK3CA, PIK3CB, PPARA, EGFR, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 7.930E-05 | 3.716E-04 | PIK3CA, PIK3CB, EGFR, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 1.872E-04 | 6.977E-04 | PIK3CA, INSR, PIK3CB, PPARA, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 2.311E-04 | 8.391E-04 | PIK3CA, SRC, PIK3CB, PTGS2, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.248E-04 | 4.993E-04 | SMAD3, PIK3CA, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 9.463E-05 | 4.195E-04 | SRC, MET, EGFR, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 3.879E-04 | 1.247E-03 | PIK3CA, CDK1, PIK3CB, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 2.460E-04 | 8.585E-04 | PIK3CA, SRC, PIK3CB, EGFR |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.248E-04 | 4.993E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.879E-04 | 1.247E-03 | PIK3CA, SRC, ALOX12, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 6.646E-04 | 2.018E-03 | PIK3CA, PIK3CB, PPARA, NFKB1, TSHR |
09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 1.614E-04 | 6.158E-04 | PIK3CA, SRC, PIK3CB, MET |
09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 2.354E-04 | 8.391E-04 | PIK3CA, PIK3CB, PTGS2, NFKB1 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.138E-03 | 3.060E-03 | FUT7, HSD17B2, CYP1A2, ALOX15, CYP1A1, AKR1B1, ALPL, ALOX12, PTGS2, CYP3A4, TYR, HSD17B10 |
09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 4.861E-04 | 1.533E-03 | SMAD3, PIK3CA, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 7.820E-04 | 2.250E-03 | PIK3CA, PIK3CB, NFKB1, HSPA1A |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 7.820E-04 | 2.250E-03 | PIK3CA, SRC, PIK3CB, ESR1 |
09150 Organismal Systems | 09151 Immune system | hsa04670 | Leukocyte transendothelial migration | 7.820E-04 | 2.250E-03 | PIK3CA, MMP2, PIK3CB, MMP9 |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.475E-03 | 3.779E-03 | PIK3CA, LMNA, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04152 | AMPK signaling pathway | 9.410E-04 | 2.616E-03 | PIK3CA, INSR, PIK3CB, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 2.102E-03 | 4.924E-03 | POLB, SMAD3, PIK3CA, PIK3CB, NFKB1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.553E-03 | 3.860E-03 | SMAD3, PIK3CA, PIK3CB, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 1.635E-03 | 3.944E-03 | PIK3CA, INSR, PIK3CB, EGFR |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 2.802E-03 | 6.382E-03 | PIK3CA, INSR, PIK3CB, ADRA2B |
09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 3.314E-03 | 7.345E-03 | PIK3CA, PIK3CB, NFKB1, HSPA1A |
09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 4.197E-03 | 8.939E-03 | PIK3CA, SRC, PIK3CB, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 4.003E-03 | 8.637E-03 | SRC, MMP2, EGFR |
09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 2.143E-03 | 4.950E-03 | PIK3CA, PIK3CB, NFKB1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 3.643E-03 | 7.965E-03 | SRC, CDK1, EGFR |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 4.254E-03 | 8.945E-03 | CSNK2A1, PTGS2, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.339E-03 | 3.487E-03 | SMAD3, PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.605E-03 | 3.928E-03 | PIK3CA, PIK3CB, MET |
09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 9.966E-04 | 2.724E-03 | PIK3CA, PIK3CB, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 8.025E-04 | 2.269E-03 | PIK3CA, PIK3CB, EGFR |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.979E-03 | 4.704E-03 | SLCO1B1, CA2, CYP3A4 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.535E-03 | 3.860E-03 | CYP1A2, CYP1A1, CYP3A4 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 6.344E-04 | 1.963E-03 | PIK3CA, INSR, PIK3CB |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.339E-03 | 3.487E-03 | ALOX15, ALOX12, PTGS2 |
09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 3.428E-04 | 1.171E-03 | PIK3CA, INSR, PIK3CB |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 3.697E-04 | 1.237E-03 | CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.406E-04 | 5.488E-04 | CYP1A2, ALOX15, CYP3A4 |
09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 2.913E-03 | 6.545E-03 | CA2, CA4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; SRC; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; FFAR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; INSR; PTGS2; FFAR1; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; INSR; |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; FFAR1; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; PTGS2; MMP1; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; INSR; EGFR; NQO2; CA9; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; PIK3CA; KDR; CSNK2A1; NFKB1; FLT3; ACHE; TEK; MMP9; EGFR; PTGS2; PIK3CB; SRC; NQO2; MMP2; CA9; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
NA: NA | Menopausal disorder | NA | ESR1; |
NA: NA | Edema | NA | CA2; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
NA: NA | GIST | NA | FLT3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; AKR1B1; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; MMP2; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; CA9; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; AKR1B1; MMP1; TYR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; MMP2; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; INSR; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; MMP2; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; MMP2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
NA: NA | Joint and muscular pain | NA | PTGS2; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
NA: NA | HIV infections | NA | AHR; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; PTGS2; MMP2; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; EGFR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; PTGS2; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; PTGS2; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
NA: NA | Rheumatold arthritis | NA | PTGS2; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; SRC; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; ALPL; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; PIK3CA; KDR; FLT3; TEK; MMP9; EGFR; PIK3CB; SRC; MMP2; CA9; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; SRC; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; INSR; PTGS2; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; PTGS2; MAPT; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |